McKesson Corporation (LON:0JZU)

Revenue

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Prescription Technology Solutions Revenue	5.65B	5.22B	4.77B
Prescription Technology Solutions Revenue Growth	8.30%	9.37%	8.71%
Medical Surgical Solutions Revenue	11.49B	11.39B	11.31B
Medical Surgical Solutions Revenue Growth	0.93%	0.65%	1.83%
US Pharmaceutical Revenue	-	327.72B	278.74B
US Pharmaceutical Revenue Growth	-	17.57%	15.84%
International Revenue	-	14.72B	14.13B
International Revenue Growth	-	4.18%	-31.40%
Revenue (Total)	397.96B	359.05B	308.95B
Revenue (Total) Growth	10.84%	16.22%	11.65%

EBIT

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Prescription Technology Solutions Operating Profit	1.01B	875.00M	835.00M
Prescription Technology Solutions Operating Profit Growth	14.97%	4.79%	47.53%
Medical Surgical Solutions Operating Profit	933.00M	773.00M	952.00M
Medical Surgical Solutions Operating Profit Growth	20.70%	-18.80%	-14.77%
US Pharmaceutical Operating Profit	-	4.00B	2.79B
US Pharmaceutical Operating Profit Growth	-	43.65%	-13.10%
International Operating Profit	-	-213.00M	319.00M
International Operating Profit Growth	-	-	134.56%
Operating Income (Other)	3.71B	-1.02B	-983.00M
Operating Income (Total)	5.65B	4.42B	3.91B
Operating Income (Total) Growth	27.84%	13.12%	-10.77%

Capital Expenditures

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
US Pharmaceutical Capital Expenditures	241.00M	193.00M
US Pharmaceutical Capital Expenditures Growth	24.87%	25.32%
Prescription Technology Solutions Capital Expenditures	11.00M	31.00M
Prescription Technology Solutions Capital Expenditures Growth	-64.52%	-11.43%
Medical Surgical Solutions Capital Expenditures	163.00M	159.00M
Medical Surgical Solutions Capital Expenditures Growth	2.52%	35.90%
International Capital Expenditures	107.00M	75.00M
International Capital Expenditures Growth	42.67%	-5.06%

Updated Dec 31, 2025. Data Source: Fiscal.ai.